Bulletin of Experimental Biology and Medicine

, Volume 137, Issue 4, pp 336–338

Mechanisms of Pefloxacin-Induced Pain

  • M. L. Kukushkin
  • S. I. Igonkina
  • T. A. Guskova
Article

Abstract

In electrophysiological and behavioral experiments on rats we studied the effects of pefloxacin, a member of fluoroquinolone family, on the nociceptive system. Intraperitoneal injection of pefloxacin (80 mg/kg) decreased the thresholds of nociceptive response to noxious stimulation in the hot-plate test. In addition, it decreased the threshold of the late component of nociceptive flexor reflex. Intrathecal application of pefloxacin in a dose of 20 μg provoked allodynia, while the higher dose of 400 μg induced behavioral pattern characteristic of central pain syndrome. It was hypothesized that pain induced by pefloxacin results from disturbances in GABAergic inhibition in the central subdivisions of the nociceptive system.

fluoroquinolone pefloxacin hyperalgesia allodynia central pain syndrome 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

REFERENCES

  1. 1.
    G. N. Kryzhanovskii, Zh. Nevropatol. Psikhiatr., 99, No. 12, 4-7 (1999).Google Scholar
  2. 2.
    G. N. Kryzhanovskii, V. K. Reshetnyak, V. A. Zinkevich, et al., Byull. Eksp. Biol. Med., 122, No. 9, 258-261 (1996).Google Scholar
  3. 3.
    M. L. Kukushkin and S. I. Igon'kina, Ibid., 135, No. 6, 647-651 (2003).Google Scholar
  4. 4.
    E. R. Padeiskaya and V. P. Yakovlev, Antimicrobial Agents of Fluoroquinolone Family in Clinical Practice [in Russian], Moscow (1998).Google Scholar
  5. 5.
    W. Christ and B. Esch, Inf. Dis. Clin. Pract., 3, 168-176 (1994).Google Scholar
  6. 6.
    J. S. Cohen, Ann. Pharmacother., 35, 1540-1547 (2001).Google Scholar
  7. 7.
    J. M. Domagala, J. Antimicrob. Chemother., 33, 685-708 (1994).Google Scholar
  8. 8.
    H. L. Du Pont, Clin. Drug Invest., 11, Suppl. 2, 25-29 (1996).Google Scholar
  9. 9.
    H. Fukuda and Y. Kawamura, Jpn. J. Antibiot., 55, No. 3, 270-280 (2002).Google Scholar
  10. 10.
    D. C. Hooper and J. S. Wolfson, in: Quinolone Antimicrobial Agents, Eds. D. C. Hooper et al., Washington (1993), pp. 482-512.Google Scholar
  11. 11.
    D. Le Bars, M. Gozariu, and S. W. Cadden, Pharmacol. Rev., 53, 597-652 (2001).Google Scholar
  12. 12.
    P. S. Lietman, Drugs, 49, Suppl. 2, 159-163 (1995).Google Scholar
  13. 13.
    N. Rosentiel and D. Adam, DrugsIbid., 47, 872-901 (1994).Google Scholar
  14. 14.
    A. Tripathi, S. I. Chen, and S. O'Sullivan, Arch. Ophtalmol., 120, 665-666 (2002).Google Scholar
  15. 15.
    T. L. Yaksh, Pain., 37, 111-123 (1989).Google Scholar

Copyright information

© Plenum Publishing Corporation 2004

Authors and Affiliations

  • M. L. Kukushkin
    • 1
  • S. I. Igonkina
    • 1
  • T. A. Guskova
    • 1
  1. 1.Laboratory of Pathophysiology of Pain, Institute of General Pathology and PathophysiologyRussian Academy of Medical SciencesMoscow

Personalised recommendations